BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18805963)

  • 1. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial.
    Pieters R; Appel I; Kuehnel HJ; Tetzlaff-Fohr I; Pichlmeier U; van der Vaart I; Visser E; Stigter R
    Blood; 2008 Dec; 112(13):4832-8. PubMed ID: 18805963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
    van der Sluis IM; de Groot-Kruseman H; Te Loo M; Tissing WJE; van den Bos C; Kaspers GJL; Bierings M; Kollen WJW; König T; Pichlmeier U; Kühnel HJ; Pieters R
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27083. PubMed ID: 29727043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia.
    van der Sluis I; Möricke A; Escherich G; von Stackelberg A; Holter W; Klingebiel T; Flotho C; Legien S; Tissing W; Bierings M; Guimbal-Schmolck C; Pichlmeier U; Kühnel HJ; Pieters R
    Haematologica; 2013 Nov; 98(11):1697-701. PubMed ID: 23753025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
    Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
    Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
    Ahlke E; Nowak-Göttl U; Schulze-Westhoff P; Werber G; Börste H; Würthwein G; Jürgens H; Boos J
    Br J Haematol; 1997 Mar; 96(4):675-81. PubMed ID: 9074406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
    Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
    Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
    Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.
    Völler S; Pichlmeier U; Zens A; Hempel G
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):305-314. PubMed ID: 29204688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
    Müller HJ; Löning L; Horn A; Schwabe D; Gunkel M; Schrappe M; von Schütz V; Henze G; Casimiro da Palma J; Ritter J; Pinheiro JP; Winkelhorst M; Boos J
    Br J Haematol; 2000 Aug; 110(2):379-84. PubMed ID: 10971395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of native Escherichia coli asparaginase.
    Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
    Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
    Müller HJ; Beier R; Löning L; Blütters-Sawatzki R; Dörffel W; Maass E; Müller-Weihrich S; Scheel-Walter HG; Scherer F; Stahnke K; Schrappe M; Horn A; Lümkemann K; Boos J
    Br J Haematol; 2001 Sep; 114(4):794-9. PubMed ID: 11564065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
    Rizzari C; Lanvers-Kaminsky C; Valsecchi MG; Ballerini A; Matteo C; Gerss J; Wuerthwein G; Silvestri D; Colombini A; Conter V; Biondi A; Schrappe M; Moericke A; Zimmermann M; von Stackelberg A; Linderkamp C; Frühwald MC; Legien S; Attarbaschi A; Reismüller B; Kasper D; Smisek P; Stary J; Vinti L; Barisone E; Parasole R; Micalizzi C; Zucchetti M; Boos J
    Haematologica; 2019 Sep; 104(9):1812-1821. PubMed ID: 30705097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
    Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
    Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of L-asparaginase in childhood ALL.
    Müller HJ; Boos J
    Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.